Rapport Therapeutics, Inc. SEC filings RAPP
Rapport Therapeutics, Inc. has 253 filings in SEC EDGAR's recent list, going back to Mar 27, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Unregistered share sale
|
Oct 30, 2026 | Oct 28, 2026 |
| 424B5 | Prospectus supplement | Oct 30, 2026 | — |
| 424B5 | Prospectus supplement | Oct 30, 2026 | — |
| 305B2 | Filing | Oct 29, 2026 | — |
| FWP | Free writing prospectus | Oct 28, 2026 | — |
| FWP | Free writing prospectus | Oct 28, 2026 | — |
| FWP | Free writing prospectus | Oct 28, 2026 | — |
| FWP | Free writing prospectus | Oct 28, 2026 | — |
| 424B5 | Prospectus supplement | Oct 27, 2026 | — |
| 424B5 | Prospectus supplement | Oct 27, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 21, 2026 | Apr 21, 2026 |
| S-3ASR | Automatic shelf registration | Mar 10, 2026 | — |
| S-8 | Employee stock plan registration | Mar 10, 2026 | — |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2026 | Mar 10, 2026 |
| 8-K |
Current report
Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 424B5 | Prospectus supplement | Jan 7, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2025 | Sep 9, 2025 |
| 424B5 | Prospectus supplement | Sep 10, 2025 | — |
| 424B5 | Prospectus supplement | Sep 8, 2025 | — |
| 8-K |
Current report
Other events
|
Sep 8, 2025 | Sep 8, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2025 | Sep 8, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2025 | Aug 7, 2025 |
| EFFECT | Filing | Jul 9, 2025 | — |
| EFFECT | Filing | Jul 9, 2025 | — |
| CORRESP | Letter to the SEC | Jul 7, 2025 | — |
| CORRESP | Letter to the SEC | Jul 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2025 | — |
| S-3 | Shelf registration | Jul 1, 2025 | — |
| S-3 | Shelf registration | Jul 1, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 2, 2025 | Jun 2, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 17, 2025 |
| S-8 | Employee stock plan registration | Mar 11, 2025 | — |
| 10-K | Annual report | Mar 11, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 10, 2025 | Jan 9, 2025 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| SEC STAFF LETTER | Filing | Jul 26, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
Jun 10, 2024 | Jun 6, 2024 |
| S-8 | Employee stock plan registration | Jun 7, 2024 | — |
| 424B4 | Prospectus | Jun 7, 2024 | — |
| EFFECT | Filing | Jun 6, 2024 | — |
| CERT | Filing | Jun 6, 2024 | — |
| 8-A12B | Filing | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | Jun 3, 2024 | — |
| S-1/A | Amended registration statement | Jun 3, 2024 | — |
| CORRESP | Letter to the SEC | May 29, 2024 | — |
| UPLOAD | Letter from the SEC | May 24, 2024 | — |
| CORRESP | Letter to the SEC | May 17, 2024 | — |
| S-1 | Registration statement | May 17, 2024 | — |
| UPLOAD | Letter from the SEC | May 13, 2024 | — |
| SEC STAFF LETTER | Filing | May 3, 2024 | — |
| DRSLTR | Filing | Apr 29, 2024 | — |
| DRS/A | Filing | Apr 29, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2024 | — |
| DRS | Filing | Mar 27, 2024 | — |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RAPP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2012593
- Former names
- Rapport Therapeutics, Inc. (until Nov 4, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.